Compare FENC & HLXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FENC | HLXC |
|---|---|---|
| Founded | 1996 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 227.2M |
| IPO Year | 2010 | N/A |
| Metric | FENC | HLXC |
|---|---|---|
| Price | $9.04 | $10.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 263.7K | 26.9K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | $906.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $10.11 |
| 52 Week High | $10.45 | $10.57 |
| Indicator | FENC | HLXC |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 63.86 |
| Support Level | $8.25 | $10.14 |
| Resistance Level | $9.15 | N/A |
| Average True Range (ATR) | 0.49 | 0.05 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 36.21 | 44.16 |
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Helix Acquisition Corp III is a blank check company.